While anti-PD-1 therapy alone is not successful at treating PDA, it synergizes with many other immunotherapies in preclinical studies and thus we are hopeful that in the near future combinations will prove efficacious in the clinic (37). Here, RPL17 is linked to Patent ductus arteriosus.